JT
ACAD icon

Jupiter Topco’s Acadia Pharmaceuticals ACAD Stock Holding History

Jupiter Topco’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Buy
+51,410
New +$1.13M ﹤0.01% 1681

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Jupiter Topco's ACAD Position: Q2 2026 in Review

Jupiter Topco opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 51,410 shares worth $1.3M. The stake represents ﹤0.01% of the portfolio and ranks #1681 among its holdings.

328 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Jupiter Topco held 51,410 shares of Acadia Pharmaceuticals worth $1.3M as of Q2 2026.
  • Acadia Pharmaceuticals was a new Jupiter Topco position in Q2 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #1681 holding.
  • 328 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.